

2024-2029 Myanmar Infectious Disease Testing Market - Virology, Bacteriology, Parasitology, Mycology - 2024 Supplier Shares, 2024-2029 Centralized and POC Volume and Sales Forecasts for 100 Respiratory, STD, Enteric, and other Microbiology Assays Performed in Hospitals, Commercial/Private Labs, POC Locations - Competitive Strategies and SWOT Analysis, Latest Technologies, Instrumentation Pipeline, Market Barriers and Risks

<https://marketpublishers.com/r/2A504591B817EN.html>

Date: December 2024

Pages: 0

Price: US\$ 1,850.00 (Single User License)

ID: 2A504591B817EN

Abstracts

This unique report from LeadingMarketResearch.com provides information not available from any other source, including test volume and sales forecasts for 100 individual tests, and competitor strategies. The report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the infectious disease testing market during the next five years. The report is available by section, and can be customized to specific information needs and budget. The report reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests; provides test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.

Rationale

This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.

The infectious disease testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.

Infectious Diseases Analyzed in the Report

AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus, Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.

Current and Emerging Products

In-depth examination of over 100 major diseases, including their etiology, current diagnostic tests, vaccines, drugs and market needs.

Review of major analyzers used for infectious disease testing, including their operating characteristics, features and selling prices.

Technology Review

Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for infectious disease testing.

Companies developing or marketing infectious disease diagnostic products by individual test.

Opportunities and Strategic Recommendations

Emerging opportunities for new instrumentation, reagents kits, IT and other products with significant market appeal during the next five years.

Design criteria for decentralized testing products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Competitive Assessments

Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new

products in R&D.

Contents

- I. Introduction
- II. Worldwide Market and Technology Overview
- A. Major Infectious Disease Tests

1. AIDS

2. ADENOVIRUS

3. AEROMONADS

4. ANTHRAX/BACILLUS ANTHRACIS

5. ARBOVIRUSES

6. BABESIOSIS

7. BACILLARY EPITHELIOID ANGIOMATOSIS (BEA)

and other Bartonella (Rochalimaea)

8. BLASTOCYSTIS HOMINIS

9. BRUCELLA

10. CAMPYLOBACTER

11. CANDIDA

12. CHAGAS DISEASE

13. CHANCROID

14. CHLAMYDIA

15. CLOSTRIDIUM DIFFICILE

16. CORONAVIRUSES

17. COXSACKIEVIRUSES

18. CREUTZFELDT-JAKOB'S DISEASE

19. CRYPTOSPORIDIUM PARVUM

20. CYCLOSPORA CAYETANENSIS

21. CYTOMEGALOVIRUS

22. EBOLA VIRUS

23. E. COLI

24. ECHOVIRUS

25. ENCEPHALITIS

26. ENTEROVIRUSES

27. EPSTEIN-BARR VIRUS

28. GIARDIA LAMBLIA

29. GONORRHEA

30. GRANULOMA INGUINALE

31. HANTAVIRUS

32. HELICOBACTER PYLORI

33. HEPATITIS

34. HERPES SIMPLEX VIRUS

35. HUMAN HERPES VIRUS-6 (HHV-6)

36. INFLUENZA VIRUSES

37. LEGIONELLA

39. LYMPHOGRANULOMA VENEREUM (LGV)

40. MALARIA

41. MEASLES (RUBEOLA)

42. MENINGITIS

43. MICROSPORIDIUM

44. MONONUCLEOSIS

45. MUMPS

46. MYCOPLASMA

47. PAPILLOMAVIRUSES

48. PARVOVIRUS B19

49. PNEUMONIA

50. POLYOMAVIRUSES

51. PSEUDOMONAS AERUGINOSA

52. RABIES

53. RESPIRATORY SYNCYTIAL VIRUS (RSV)

54. RHINOVIRUSES

55. ROTAVIRUS (REOVIRUS)

56. RUBELLA (MEASLES)

57. SALMONELLOSIS

58. SEPTICEMIA

59. SHIGELLOSIS

60. STAPHYLOCOCCUS AUREUS

61. STREPTOCOCCI

62. SYPHILIS

63. TOXOPLASMOSIS

64. TRICHOMONAS VAGINALIS

65. TUBERCULOSIS

66. VIBRIO

67. WEST NILE VIRUS

68. YERSINA

B. Instrumentation Review: Operating Characteristics,
Features and Selling Princes of Leading Automated
and Semi-automated Analyzers

C. Emerging Diagnostic Technologies

III. Market Size, Growth and Sales Forecasts by Test

IV. Major Product Development Opportunities

V. Design Criteria for Decentralized Testing Products

VI. Alternative Market Penetration Strategies

VII. Distribution Strategies for Decentralized
Testing Markets

VIII. Potential Market Entry Barriers and Risks

IX. Competitive Assessments

Abbott

Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Decode Genetics
Eiken Chemical
Elitech Group
Enzo Biochem
Exact Sciences
Fujifilm Wako
Fujirebio
Grifols
Hologic
Illumina
Leica Biosystems
Li-Cor Biosciences
Myriad Genetics
PerkinElmer
Proteome Sciences
Qiagen
Quest Diagnostics
QuidelOrtho
Roche
Scienion
Sequenom/LabCorp
Shimadzu
Siemens Healthineers
Sierra Molecular
Takara Bio
Tecan Group
Thermo Fisher

I would like to order

Product name: 2024-2029 Myanmar Infectious Disease Testing Market - Virology, Bacteriology, Parasitology, Mycology - 2024 Supplier Shares, 2024-2029 Centralized and POC Volume and Sales Forecasts for 100 Respiratory, STD, Enteric, and other Microbiology Assays Performed in Hospitals, Commercial/Private Labs, POC Locations - Competitive Strategies and SWOT Analysis, Latest Technologies, Instrumentation Pipeline, Market Barriers and Risks

Product link: <https://marketpublishers.com/r/2A504591B817EN.html>

Price: US\$ 1,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2A504591B817EN.html>